08:42 AM EST, 12/27/2024 (MT Newswires) -- BioNTech (BNTX) has entered into two separate settlements with the US National Institutes of Health and the University of Pennsylvania over royalties on sales of the company's Covid-19 vaccine, separate filings showed Friday.

Without admitting liability, the biotechnology company said it agreed to pay $791.5 million to the NIH and $467 million to UPenn for, among others, claimed royalties from 2020 to 2023, according to the filings.

BioNTech also said Pfizer ( PFE ) agreed to reimburse $364.5 million of NIH's claimed royalties and up to $170 million of the amount payable to UPenn.